To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

Sandoz

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH); Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00881153

AA17502

Details and patient eligibility

About

The purpose of this study is to Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

Enrollment: 20 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

1

Experimental group

Description:

Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)

Treatment:

Drug: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)

2

Active Comparator group

Description:

Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)

Treatment:

Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)